https://newsletter.glp1studio.com/archivedailyhttps://newsletter.glp1studio.com/aboutweeklyhttps://newsletter.glp1studio.com/podcastweeklyhttps://newsletter.glp1studio.com/p/novo-nordisk-sues-a-generic-drugmaker2026-09-19monthlyhttps://newsletter.glp1studio.com/p/she-says-a-glp-1-stopped-her-drinking2026-09-19monthlyhttps://newsletter.glp1studio.com/p/three-new-lawsuits-land-against-lilly2026-09-18monthlyhttps://newsletter.glp1studio.com/p/advil-maker-stocks-shelves-near-the2026-09-18monthlyhttps://newsletter.glp1studio.com/p/a-house-bill-on-pharmacy-middlemen2026-09-17monthlyhttps://newsletter.glp1studio.com/p/berenberg-sees-more-upside-for-lilly2026-09-17monthlyhttps://newsletter.glp1studio.com/p/six-new-lawsuits-hit-novo-nordisk2026-09-16monthlyhttps://newsletter.glp1studio.com/p/arbor-locks-compounded-glp-1-prices2026-09-16monthlyhttps://newsletter.glp1studio.com/p/illinois-may-cut-compounded-glp-1s2026-09-16monthlyhttps://newsletter.glp1studio.com/p/six-pending-lawsuits-could-reshape2026-09-16monthlyhttps://newsletter.glp1studio.com/p/old-mice-on-semaglutide-lived-about2026-09-16monthlyhttps://newsletter.glp1studio.com/p/chobani-is-sued-over-what-its-labels2026-09-15monthlyhttps://newsletter.glp1studio.com/p/a-new-glp-1-will-be-tested-as-a-switch2026-09-14monthlyhttps://newsletter.glp1studio.com/p/restaurants-are-shrinking-portions2026-09-16monthlyhttps://newsletter.glp1studio.com/p/three-new-lawsuits-target-how-much2026-09-16monthlyhttps://newsletter.glp1studio.com/p/glp1s-and-genetics2026-09-13monthlyhttps://newsletter.glp1studio.com/p/rhode-island-medicaid-stops-covering2026-09-14monthlyhttps://newsletter.glp1studio.com/p/cramer-picks-j-and-j-over-lilly-and2026-09-16monthlyhttps://newsletter.glp1studio.com/p/cramer-calls-lilly-a-must-own-as2026-09-16monthlyhttps://newsletter.glp1studio.com/p/a-5-year-study-asks-if-semaglutide2026-09-16monthlyhttps://newsletter.glp1studio.com/p/a-patent-challenge-could-shorten2026-09-14monthlyhttps://newsletter.glp1studio.com/p/a-uk-study-found-fewer-asthma-attacks2026-09-16monthlyhttps://newsletter.glp1studio.com/p/what-viking-needs-to-hit-that-922026-09-16monthlyhttps://newsletter.glp1studio.com/p/amgen-starts-human-testing-on-its2026-09-14monthlyhttps://newsletter.glp1studio.com/p/novo-plants-a-flag-in-india-with2026-09-16monthlyhttps://newsletter.glp1studio.com/p/novo-nordisk-starts-small-trial-of2026-09-14monthlyhttps://newsletter.glp1studio.com/p/one-patent-case-could-undercut-ozempics2026-09-14monthlyhttps://newsletter.glp1studio.com/p/mounjaros-heart-data-could-open-a2026-09-16monthlyhttps://newsletter.glp1studio.com/p/what-ozempic-can-and-cant-do-according2026-09-16monthlyhttps://newsletter.glp1studio.com/p/delaware-moves-on-pbms-while-two2026-09-14monthlyhttps://newsletter.glp1studio.com/p/druckenmiller-and-griffin-both-bought2026-09-16monthlyhttps://newsletter.glp1studio.com/p/washington-state-takes-novo-nordisk2026-09-14monthlyhttps://newsletter.glp1studio.com/p/alison-hammond-gets-candid-on-ozempic2026-09-16monthlyhttps://newsletter.glp1studio.com/p/two-drugmakers-one-legal-argument2026-09-14monthlyhttps://newsletter.glp1studio.com/p/africa-becomes-lillys-next-big-mounjaro2026-09-16monthlyhttps://newsletter.glp1studio.com/p/now-a-dozen-lawsuits-accuse-novo2026-09-14monthlyhttps://newsletter.glp1studio.com/p/snoring-may-be-the-next-glp-1-benefit2026-09-16monthlyhttps://newsletter.glp1studio.com/p/semaglutide-now-faces-a-5-year-test2026-09-14monthlyhttps://newsletter.glp1studio.com/p/citi-downgrades-novo-nordisk-on-slowing2026-09-16monthlyhttps://newsletter.glp1studio.com/p/a-daily-glp-1-pill-just-cleared-its2026-09-14monthlyhttps://newsletter.glp1studio.com/p/novo-nordisk-shifts-its-glp-1-strategy2026-09-16monthlyhttps://newsletter.glp1studio.com/p/six-lawsuits-now-claim-novo-and-lilly2026-09-14monthlyhttps://newsletter.glp1studio.com/p/who-actually-gets-medicares-50-glp2026-09-16monthlyhttps://newsletter.glp1studio.com/p/fda-tightens-rules-on-where-your2026-09-08monthlyhttps://newsletter.glp1studio.com/p/mounjaro-can-now-claim-it-protects2026-09-16monthlyhttps://newsletter.glp1studio.com/p/mounjaro-wins-fda-approval-for-heart2026-09-16monthlyhttps://newsletter.glp1studio.com/p/hair-loss-risk-emerges-as-glp-1-drug2026-09-16monthlyhttps://newsletter.glp1studio.com/p/lillys-pill-form-glp-1-is-still-years2026-09-09monthlyhttps://newsletter.glp1studio.com/p/50-obesity-drugs-200000-prescriptions2026-09-16monthlyhttps://newsletter.glp1studio.com/p/seven-lawsuits-now-target-how-novo2026-09-09monthlyhttps://newsletter.glp1studio.com/p/novo-nordisk-faces-a-wave-of-lawsuits2026-09-09monthlyhttps://newsletter.glp1studio.com/p/100000-scripts-in-at-50-a-month-for2026-09-16monthlyhttps://newsletter.glp1studio.com/p/astrazeneca-loses-again-on-medicare2026-09-16monthlyhttps://newsletter.glp1studio.com/p/four-lawsuits-now-question-how-glp2026-09-09monthlyhttps://newsletter.glp1studio.com/p/why-states-said-no-to-cheaper-wegovy2026-09-16monthlyhttps://newsletter.glp1studio.com/p/two-lawsuits-accuse-novo-nordisk2026-09-09monthlyhttps://newsletter.glp1studio.com/p/states-reject-trumps-discount-deal2026-09-16monthlyhttps://newsletter.glp1studio.com/p/can-gut-supplements-make-ozempic2026-09-16monthlyhttps://newsletter.glp1studio.com/p/obesity-drugs-now-dominate-the-pharma2026-09-16monthlyhttps://newsletter.glp1studio.com/p/semaglutides-next-test-is-whether2026-09-09monthlyhttps://newsletter.glp1studio.com/p/novo-hunts-for-smallest-dose-that2026-09-16monthlyhttps://newsletter.glp1studio.com/p/lillys-pill-form-glp-1-is-being-tested2026-09-09monthlyhttps://newsletter.glp1studio.com/p/illinois-workers-comp-bill-could2026-09-08monthlyhttps://newsletter.glp1studio.com/p/hims-and-hers-ceo-defends-company2026-09-16monthlyhttps://newsletter.glp1studio.com/p/nestle-turns-to-ai-to-feed-the-ozempic2026-09-16monthlyhttps://newsletter.glp1studio.com/p/pcos-symptoms-may-ease-on-weight2026-09-16monthlyhttps://newsletter.glp1studio.com/p/glp-1-drugs-may-ease-pcos-symptoms2026-09-16monthlyhttps://newsletter.glp1studio.com/p/why-you-might-see-a-serena-williams2026-09-16monthlyhttps://newsletter.glp1studio.com/p/novo-nordisk-ceo-defends-lawsuit-5f92026-09-16monthlyhttps://newsletter.glp1studio.com/p/two-obesity-pills-are-still-stuck2026-09-09monthlyhttps://newsletter.glp1studio.com/p/what-changed-for-glp-1-access-thursday2026-09-08monthlyhttps://newsletter.glp1studio.com/p/novo-nordisk-ceo-defends-lawsuit2026-09-16monthlyhttps://newsletter.glp1studio.com/p/eli-lilly-wins-uk-approval-challenging2026-09-16monthlyhttps://newsletter.glp1studio.com/p/lillys-four-new-lawsuits-target-the2026-09-09monthlyhttps://newsletter.glp1studio.com/p/vegan-diet-shows-weight-loss-comparable-a9b2026-09-16monthlyhttps://newsletter.glp1studio.com/p/what-changed-for-glp-1-access-tuesday-eab2026-09-08monthlyhttps://newsletter.glp1studio.com/p/two-new-trials-expand-who-glp-1-drugs2026-09-09monthlyhttps://newsletter.glp1studio.com/p/vegan-diet-shows-weight-loss-comparable2026-09-16monthlyhttps://newsletter.glp1studio.com/p/1-coverage-for-weight-loss-as-costs2026-09-16monthlyhttps://newsletter.glp1studio.com/p/lilly-novo-defeat-antitrust-lawsuit-af22026-09-16monthlyhttps://newsletter.glp1studio.com/p/lilly-novo-defeat-antitrust-lawsuit2026-09-16monthlyhttps://newsletter.glp1studio.com/p/were-increasing-our-eli-lilly-price2026-09-16monthlyhttps://newsletter.glp1studio.com/p/lilly-is-suing-everyone-who-might2026-09-09monthlyhttps://newsletter.glp1studio.com/p/novo-nordisk-releases-earnings-and2026-09-16monthlyhttps://newsletter.glp1studio.com/p/what-changed-for-glp-1-access-wednesday2026-09-08monthlyhttps://newsletter.glp1studio.com/p/eli-lilly-to-offer-early-access-to2026-09-16monthlyhttps://newsletter.glp1studio.com/p/what-changed-for-glp-1-access-tuesday2026-09-08monthlyhttps://newsletter.glp1studio.com/p/a-new-lawsuit-hits-novo-nordisk-and2026-09-09monthlyhttps://newsletter.glp1studio.com/p/for-glp-1-users-the-in-store-clothes2026-09-16monthlyhttps://newsletter.glp1studio.com/p/direct-glp-1-prescriptions-are-walmart2026-09-16monthlyhttps://newsletter.glp1studio.com/p/two-new-trials-test-what-happens2026-09-09monthlyhttps://newsletter.glp1studio.com/p/novo-nordisks-market-value-sheds2026-09-16monthlyhttps://newsletter.glp1studio.com/p/a-glp-1-harm-lawsuit-against-lilly2026-09-09monthlyhttps://newsletter.glp1studio.com/p/brazil-greenlights-five-new-injectable2026-09-16monthlyhttps://newsletter.glp1studio.com/p/eight-lawsuits-pile-up-against-novo2026-09-09monthlyhttps://newsletter.glp1studio.com/p/two-patients-take-novo-nordisk-and2026-09-09monthlyhttps://newsletter.glp1studio.com/p/two-lawsuits-target-glp-1-makers2026-09-09monthlyhttps://newsletter.glp1studio.com/p/semaglutide-may-be-changing-how-the2026-09-09monthlyhttps://newsletter.glp1studio.com/p/amgen-tests-whether-maritide-interferes2026-09-09monthlyhttps://newsletter.glp1studio.com/p/virginia-could-cut-off-compounded2026-09-09monthlyhttps://newsletter.glp1studio.com/p/lillys-glp-1-pill-clears-an-early-2412026-09-09monthlyhttps://newsletter.glp1studio.com/p/new-glp-1-drugs-are-being-tested2026-09-09monthlyhttps://newsletter.glp1studio.com/p/a-tiny-trial-asks-if-tirzepatide2026-09-09monthlyhttps://newsletter.glp1studio.com/p/your-genes-may-explain-why-oral-semaglutide2026-09-09monthlyhttps://newsletter.glp1studio.com/p/a-new-diabetes-drug-just-took-on2026-09-09monthlyhttps://newsletter.glp1studio.com/p/when-a-cheaper-glp-1-actually-arrives2026-09-06monthlyhttps://newsletter.glp1studio.com/p/the-compounded-glp-1-cliff-what-the2026-09-06monthlyhttps://newsletter.glp1studio.com/p/why-your-glp-1-coverage-depends-on2026-09-06monthlyhttps://newsletter.glp1studio.com/p/semaglutide-moves-into-a-teen-obesity2026-09-09monthlyhttps://newsletter.glp1studio.com/p/canada-will-test-tirzepatide-as-a2026-09-09monthlyhttps://newsletter.glp1studio.com/p/a-semaglutide-implant-under-your2026-09-09monthlyhttps://newsletter.glp1studio.com/p/you-have-more-time-to-weigh-in-on2026-09-09monthlyhttps://newsletter.glp1studio.com/p/the-government-wants-your-input-on2026-09-09monthlyhttps://newsletter.glp1studio.com/p/two-more-glp-1-drugs-are-years-from2026-09-09monthlyhttps://newsletter.glp1studio.com/p/a-blacklisted-chinese-drugmaker-could2026-09-09monthlyhttps://newsletter.glp1studio.com/p/lillys-pill-clears-a-kidney-safety2026-09-09monthlyhttps://newsletter.glp1studio.com/p/semaglutides-walking-test-results2026-09-09monthlyhttps://newsletter.glp1studio.com/p/lillys-glp-1-pill-clears-an-early2026-09-09monthlyhttps://newsletter.glp1studio.com/p/a-new-obesity-drug-moves-into-testing2026-09-09monthlyhttps://newsletter.glp1studio.com/p/compounded-ozempic-and-mounjaro-are2026-09-09monthlyhttps://newsletter.glp1studio.com/p/senior-living-what-americans-should2026-09-16monthlyhttps://newsletter.glp1studio.com/p/taiwan-trial-pits-tirzepatide-against2026-09-09monthlyhttps://newsletter.glp1studio.com/p/medicare-coverage-for-glp-1-weight-7cf2026-09-16monthlyhttps://newsletter.glp1studio.com/p/pbm-rules-are-deciding-who-gets-a2026-09-08monthlyhttps://newsletter.glp1studio.com/p/medicare-coverage-for-glp-1-weight2026-09-16monthlyhttps://newsletter.glp1studio.com/p/compounded-glp1-policy-update-may-20262026-05-08monthlyhttps://newsletter.glp1studio.com/p/glp1-sharps-disposal2026-05-07monthlyhttps://newsletter.glp1studio.com/p/glp1-employer-coverage-without-insurance-andel2026-04-08monthlyhttps://newsletter.glp1studio.com/p/bariatric-surgery-vs-glp1-medication2026-03-22monthlyhttps://newsletter.glp1studio.com/p/sabina-glpwinner2026-02-16monthlyhttps://newsletter.glp1studio.com/p/fda-hims-and-hers-semaglutide-pill2026-02-24monthlyhttps://newsletter.glp1studio.com/p/2025-amanda-bonello2026-02-10monthlyhttps://newsletter.glp1studio.com/p/shotsy2026-01-12monthlyhttps://newsletter.glp1studio.com/p/biocare2026-01-04monthlyhttps://newsletter.glp1studio.com/p/ozempic-saved-my-life2026-02-04monthlyhttps://newsletter.glp1studio.com/p/dr-nina-crowley2025-11-20monthlyhttps://newsletter.glp1studio.com/p/medicaide-medicare-glp1-coverage2026-02-10monthlyhttps://newsletter.glp1studio.com/p/trumprx-glp1s2025-11-11monthlyhttps://newsletter.glp1studio.com/p/nicky-cayan2025-10-25monthlyhttps://newsletter.glp1studio.com/p/dr-angela-tran2025-10-07monthlyhttps://newsletter.glp1studio.com/p/glp-1-studio-podcast2025-10-07monthlyhttps://newsletter.glp1studio.com/p/dr-craig-primack2025-09-22monthlyhttps://newsletter.glp1studio.com/p/alnu-health2025-09-11monthlyhttps://newsletter.glp1studio.com/p/justin-silver-founder-of-symptoguard2025-08-26monthlyhttps://newsletter.glp1studio.com/p/glp1hub2025-11-26monthlyhttps://newsletter.glp1studio.com/p/glp1-patents2026-02-09monthlyhttps://newsletter.glp1studio.com/p/season-2-episode-1-sharna-braucks2025-09-22monthlyhttps://newsletter.glp1studio.com/p/erica-koffler2025-09-29monthlyhttps://newsletter.glp1studio.com/p/tahir-amin-the-research-behind-the-7db2026-09-12monthlyhttps://newsletter.glp1studio.com/p/jamie-selzler-living-proof-that-its-fc32025-09-22monthlyhttps://newsletter.glp1studio.com/p/beth-laf-the-everyday-advocate-a532026-09-12monthlyhttps://newsletter.glp1studio.com/p/contact-congress-for-glp1-access2026-02-05monthlyhttps://newsletter.glp1studio.com/p/sarah-baker-force-of-nature-2c62026-09-12monthlyhttps://newsletter.glp1studio.com/p/pureway-compliance-sharps-support-b992026-09-12monthlyhttps://newsletter.glp1studio.com/p/lost-glp1-coverage-through-employer2026-09-12monthlyhttps://newsletter.glp1studio.com/p/ruth-ceretto-jack-of-all-trades-1a82026-09-12monthlyhttps://newsletter.glp1studio.com/p/imak-glp1-report2026-02-09monthlyhttps://newsletter.glp1studio.com/p/fda-petition2026-02-09monthlyhttps://newsletter.glp1studio.com/p/amanda-fratello-trapped-a-the-fight-7742026-09-12monthlyhttps://newsletter.glp1studio.com/p/glp1-coverage-for-teens-one-moms-fight2026-09-12monthlyhttps://newsletter.glp1studio.com/p/dana-greene-the-most-motivating-force-0fb2026-09-12monthlyhttps://newsletter.glp1studio.com/p/liz-chalmers-mother-business-owner-d3b2026-09-12monthlyhttps://newsletter.glp1studio.com/p/dr-lindsay-ogle2026-01-21monthlyhttps://newsletter.glp1studio.com/p/elizabeth-walker-the-heart-of-a-healer-0392026-09-12monthlyhttps://newsletter.glp1studio.com/p/kerileigh-parker-mast-a-story-of-ddf2026-09-12monthlyhttps://newsletter.glp1studio.com/p/amanda-bonello-the-voice-behind-the-b952026-09-12monthlyhttps://newsletter.glp1studio.com/p/jackson-lemay-the-glp-1-community-0a62026-09-12monthlyhttps://newsletter.glp1studio.com/p/kim-carlos-from-the-plus-sidez-podcast-19e2026-09-12monthlyhttps://newsletter.glp1studio.com/p/zepbound-before-and-after-weight-loss-cycling2026-09-12monthlyhttps://newsletter.glp1studio.com/p/glp1-studio-podcast2026-03-22monthly